Nanos1 Antibody | 4683

Nanos1 Antibody | 4683 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: Predicted species reactivity based on immunogen sequence: Mouse: (88%)

Immunogen: Nanos1 antibody was raised against a 17 amino acid synthetic peptide from near the amino terminus of human Nanos1.
The immunogen is located within the first 50 amino acids of Nanos1.

Research Area: Signal Transduction

Tested Application: E, WB, IHC-P, IF

Application: Nanos1 antibody can be used for detection of Nanos1 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1220 - SK-N-SH Cell Lysate

Positive Control 2: Cat. No. 10-301 - Human Brain Tissue Slide

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Nanos1 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Nanos1 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: Nanos1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: Nanos1 Antibody: NOS1, SPGF12, NOS1, Nanos homolog 1, NOS-1

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Nanos1 Antibody: Nanos1 is one of three known mammalian homologs to the Drosophila gene nanos. Nanos1 is an RNA-binding protein containing a zinc-finger motif and is expressed in the developing nervous system and continues in the adult brain. Interestingly, unlike mice deficient in either nanos2 or nanos3, mice lacking the nanos1 gene develop normally with no sign of abnormalities. Recently it has been found that expression of nanos1 mRNA is down-regulated by E-cadherin in a human breast cancer cell line and the amino-terminal domain on Nanos1 interacts with the E-cadherin-binding protein p120ctn. Furthermore, overexpression of Nanos1 in human colorectal DLD1 cancer cells functionally abolished cell-cell adhesion, allowing the cancer cells to develop strong migratory and invasive properties. These results suggest that targeting Nanos1 might prove an effective strategy in the treatment of E-cadherin-negative tumors.